Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: Retrospective analysis of the AVAglio trial

Journal of Clinical Oncology

Volumn 33, Issue 25, 2015, Pages 2735-2744

  Sandmann, Thomas ^a   Bourgon, Richard ^a   Garcia, Josep ^c   Li, Congfen ^a   Cloughesy, Timothy ^b   Chinot, Olivier L ^d   Wick, Wolfgang ^e   Nishikawa, Ryo ^f   Mason, Warren ^g   Henriksson, Roger ^h,i   Saran, Frank ^j   Lai, Albert ^b   Moore, Nicola ^c   Kharbanda, Samir ^a   Peale, Franklin ^a   Hegde, Priti ^a   Abrey, Lauren E ^c   Phillips, Heidi S ^a   Bais, Carlos ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d AIX MARSEILLE UNIVERSITY   (France)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h Regional Cancer Center Stockholm ^*  (Sweden)

ⁱ UMEÅ UNIVERSITY   (Sweden)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CORTICOSTEROID; ISOCITRATE DEHYDROGENASE 1; PLACEBO; TEMOZOLOMIDE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; DACARBAZINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADD ON THERAPY; ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COVARIANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GLIOBLASTOMA; HAZARD RATIO; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MESENCHYME; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT DURATION; WILD TYPE; ADJUVANT RADIOTHERAPY; AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STAGING; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BEVACIZUMAB; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84941359544     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.5005     Document Type: Article

References (33)

1. Ostrom QT, Gittleman H, Liao P, et al: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16:iv1-iv63, 2014 (suppl 4)
2. National Comprehensive Cancer Network: NCCN guidelines: Central nervous system cancers (version 1.2012). http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
4. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
5. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
6. Weller M, Felsberg J, Hartmann C, et al: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750, 2009
7. Brandes AA, Tosoni A, Franceschi E, et al: Glioblastoma in adults. Crit Rev Oncol Hematol 67:139-152, 2008
8. Electronic Medicines Compendium: Avastin undesirable effects. http://www.medicinesorg.uk/emc/medicine/15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/#UNDESIRABLE-EFFECTS
9. Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
10. Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014
11. Fine HA: Bevacizumab in glioblastoma: Still much to learn. N Engl J Med 370:764-765, 2014
12. Lai A, Kharbanda S, Pope WB, et al: Evidence for sequenced molecular evolution of idh1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482-4490, 2011
13. Ohgaki H, Kleihues P: The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764-772, 2013
14. Phillips HS, Kharbanda S, Chen RH, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006
15. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
16. Brennan CW, Verhaak RG, McKenna A, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
17. Naeini KM, Pope WB, Cloughesy TF, et al: Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol 15:626-634, 2013
18. Ozawa T, Riester M, Cheng YK, et al: Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell 26:288-300, 2014
19. Huse JT, Phillips HS, Brennan CW: Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia 59:1190-1199, 2011
20. Capper D, Zentgraf H, Balss J, et al: Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599-601, 2009
21. Geiss GK, Bumgarner RE, Birditt B, et al Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317-325, 2008
22. Harbron C, Chang KM, South MC: RefPlus: An R package extending the RMA algorithm. Bioinformatics 23:2493-2494, 2007
23. Therneau T: A package for survival analysis in S. R package version 2.37-7. http://CRAN.R-projectorg/package=survival
24. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800-802, 1988
25. Reis PP, Waldron L, Goswami RS, et al mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 11:46, 2011
26. Prokopec SD, Watson JD, Waggott DM, et al: Systematic evaluation of medium-throughput mRNA abundance platforms. RNA 19:51-62, 2013
27. Bais C, Rabe C, Wild N, et al: Comprehensive re-assessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in thirteen pivotal trials (seven indications). J Clin Oncol 32:189s, 2014 (suppl 15s; abstr 3040)
28. Lambrechts D, Lenz HJ, de Haas S, et al: Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219-1230, 2013
29. Jubb AM, Hurwitz HI, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer. J Clin Oncol 24:217-227, 2006
30. Brauer MJ, Zhuang GL, Schmidt M, et al: Identification and analysis of in vivo VEGF downstream markers link VEGF Pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 19:3681-3692, 2013
31. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893, 2002
32. Sulman EP, Won M, Blumenthal DT, et al: Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 31: 116s, 2013 (suppl 15s; abstr LBA2010)
33. Piao Y, Liang J, Holmes L, et al: Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 19:4392-4403, 2013